Podcasts about Evaluation

#135 Rebroadcast Well guess what, Melissa is a PhD Doctor now! And you know what that means? She gets to tell us more details about the research she did to get her PhD. Listen to hear what Melissa found as she dove deep into the question "Why do people hate organic chemistry?" for the past few years. References from this episode National Research Council, (2012), Discipline-based education research: Understanding and improving learning in undergraduate science and engineering, The National Academies Press. Graulich N., (2015), The tip of the iceberg in organic chemistry classes: How do students deal with the invisible? Chem. Educ. Res. Pract., 16(1), 9–21. Xu X. and Lewis J. E., (2011), Refinement of a chemistry attitude measure for college students. J. Chem. Educ., 88(5), 561–568. Gibbons R. E. and Raker J. R., (2019), Self-beliefs in organic chemistry: Evaluation of a reciprocal causation, cross-lagged model. J. Res. Sci. Teach., 56(5), 598–618.   Support this podcast on Patreon Buy Podcast Merch and Apparel Check out our website at chemforyourlife.com Watch our episodes on YouTube Find us on Instagram, Twitter, and Facebook @ChemForYourLife   Thanks to our monthly supporters Sara Hull Dog Day Dan Bri . Summer Alden Amanda Raymond Kyle McCray Justine Ash Vince W Julie S. Heather Ragusa Autoclave Dorien VD Scott Beyer Jessie Reder J0HNTR0Y Cullyn R Erica Bee Elizabeth P Rachel Reina Letila Katrina Barnum-Huckins Suzanne Phillips Venus Rebholz Jacob Taber Brian Kimball Kristina Gotfredsen Timothy Parker Steven Boyles Chris Skupien Chelsea B Avishai Barnoy Hunter Reardon   Support this podcast on Patreon Buy Podcast Merch and Apparel Check out our website at chemforyourlife.com Watch our episodes on YouTube Find us on Instagram, Twitter, and Facebook @ChemForYourLife Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Connor and Mike determine which Husker football position group they're confident in, they're more curious about, and they think is a liability.

Micke Sundell (MoDo), Félix Bibeau (Chicoutimi Saguenéens) and Mário Bližňák (HK Dukla Trenčín) join host Jesse Cohen to discuss the first three players selected by the Kings at the 2026 NHL Entry Draft.Elton Hermansson, Liam Lefebvre and Adam Goljer were selected with the 19th, 46th and 49th picks overall.

Is internal evaluation the gold standard in pelvic health?  We believe the answer is yes.Lately, we've seen more clinicians claiming that internal pelvic floor evaluation isn't necessary—or isn't the gold standard of pelvic rehab. We don't think this is just another social media debate.We think it's one of the most important conversations our profession needs to have.We're going to be diving deep into this topic.  But for Part 1, we discuss: Why this issue matters so much for the future of pelvic health  What the pioneers of our profession fought to establish  The strongest arguments against internal evaluation—and where we think they fall short  Why "access to care" shouldn't mean lowering the standard of care  Why extraordinary claims require extraordinary evidence (Also, the caveat we shouldn't need....Every internal evaluation should be clinically appropriate and performed only with informed patient consent.  Of course.)Instead, this episode asks a bigger question:  What should the gold standard actually be for pelvic rehab?About Nicole & Jesse CozeanPelvic health is hard. We want everyone in this field to have a joyful, impactful career. And for business owners to build something that truly works for them.

Michelle Rhee, a a Venture Partner at Equal Opportunity Ventures and the former chancellor of Washington, D.C., Public Schools, joins Paul E. Peterson to discuss the future of Washington schools under presumptive mayor Janeese Lewis George.

Romans 8 is among the most famous chapters in all the Bible. Christians have hoped and found freedom in these words for centuries. This glorious chapter begins with a verse often quoted today: “There is therefore now no condemnation for those who are in Christ Jesus.” (8:1) But what does that mean for followers of Jesus? In this message, we will define condemnation's biblical meaning, trace its use through Romans, then spend most of our time applying what it means for the believer's life today.Take-Home Message (Romans 8:1): There is therefore now no condemnation for those who are in Christ Jesus.A Biblical Definition of Condemnation: The judicial verdict of condemnation issued against a guilty party. It describes the divine sentence that looms over all humanity because of Adam's fall and our universal sin. It can also be translated as “death sentence.” Tracing Condemnation Through Romans:Condemnation enters through Adam's sin. Condemnation is universal.Condemnation is conquered by Christ's act of righteousness.Condemnation is replaced with Christ's righteousness for the believer.There is now no condemnation for those who are in Christ Jesus.What Does No Condemnation in Christ Jesus Mean for Believers?My eternal condemnation is removed.Evaluation of my life remains.Conviction replaces my condemnation.I am freed to confess my sin.Evangelism and missions matter.I worship Christ Jesus because He freed me from condemnation.

What if PCOS was never just about the ovaries, but about a deeper hormonal, metabolic, and nervous system pattern that could also be affecting your migraines?In this episode of Migraine Heroes Podcast, host Diane Ducarme explores the proposed shift from PCOS to PMOS, and why this new name may help migraine sufferers better understand symptoms that often feel disconnected, confusing, or random.You'll discover:

Listen to the Jay Garvens Home & Mortgage Show as Jay and his special guest Ken Smith from Churchill Mortgage delivers the-Mid Year Market Evaluation 2.0 here on KRDO News Radio 105.5fm and 1240am

Listen to the Jay Garvens Home & Mortgage Show as Jay and his special guest Ken Smith from Churchill Mortgage delivers the-Mid Year Market Evaluation 2.0 here on KRDO News Radio 105.5fm and 1240am

Like tens of millions of people, Stephen Dubner thought he had a penicillin allergy. Like the vast majority, he didn't. This misdiagnosis costs billions of dollars and causes serious health problems, so why hasn't it been fixed? We find out in this update of a 2025 episode.   SOURCES: Kimberly Blumenthal, allergist-immunologist and researcher at the Mayo Clinic. Theresa MacPhail, associate professor of science and technology studies at Stevens Institute of Technology. Thomas Platts-Mills, professor of medicine at the University of Virginia. Elena Resnick, allergist and immunologist at Mount Sinai Hospital.   RESOURCES: Allergic: Our Irritated Bodies in a Changing World, by Theresa MacPhail (2023). "Evaluation and Management of Penicillin Allergy: A Review," by Erica S. Shenoy, Eric Macy, and Theresa Rowe (JAMA, 2019). "The Allergy Epidemics: 1870–2010," by Thomas Platts-Mills (The Journal of Allergy and Clinical Immunology, 2016). "Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy," by George Du Toit, Graham Roberts, et al. (The New England Journal of Medicine, 2015).   EXTRAS: "The Freakonomics Radio Guide to Getting Better," series by Freakonomics Radio (2026). "Doctors Know They Prescribe Too Many Antibiotics. Why Don't They Stop?" by Freakonomics, M.D. (2022). Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Don and Professor Ben talk about the risks of aspirin canning. Dr. Don - risky ☣️ Professor Ben - risky ☣️ Carla Schwan | UGA FACS Home - IAFNS Vegetables and Fruits FAQs - National Center for Home Food Preservation Aspirin - Wikipedia Canning With Aspirin Instead of Sugar – Front page story – Finding Eliza Regional Variations in Home Canning Practices and the Risk of Foodborne Botulism in the Republic of Georgia, 2003 - ScienceDirect Use of Aspirin (Salicylic acid) as food preservative - good or bad? : r/foodscience Evaluation of the effect of acetylsalicylic acid on Clostridium botulinum growth and toxin production - PubMed Salicylic acids and pathogenic bacteria: new perspectives on an old compound

Hour 1 -- Copes and Ted Ramey give their thoughts on the Giants first half of the season. They also dive into Buster Posey's interview with the morning show and discuss Buster's thoughts heading into the trade deadline.See omnystudio.com/listener for privacy information.

Send us Fan MailGuests: Dr. Amy Nunn, CEO, Rhode Island Public Health InstituteChris Buchanan Director of Public Affairs and State and Local Government Relations with Walmart Stores, IncIn this episode, we explore the innovative Eat Well, Be Well program in Rhode Island, which successfully leverages public-private partnerships to promote healthy eating among SNAP recipients. Discover how automating incentives at checkout can increase fruit and vegetable consumption, and the potential for these strategies to scale into other areas of health and wellbeing.Main Topics:The origin and goals of the Eat Well, Be Well initiativeHow the program doubles the value of SNAP benefits for produce in retail locationsThe seamless, no-signup approach that simplifies access to healthy foodsThe role of technology in efficient program administrationData and impact: how the program benefits thousands of Rhode IslandersStrategies for scaling similar incentive models to broader health behaviorsFuture expansion possibilities beyond produce, including active lifestylesThe importance of cross-sector collaboration in shaping healthier communitiesTimestamps:00:00 - Introduction to the episode and guests00:16 - Guest introductions: Chris Buchanan and Dr. Amy Nunn01:04 - The purpose and history of the Eat Well, Be Well program01:33 - How the program supports affordability of healthy foods for SNAP recipients02:10 - Program funding sources and extension through COVID relief dollars02:55 - Walmart's involvement: why they joined the pilot program03:27 - Making healthy shopping affordable and practical03:57 - Seamless incentive application at checkout05:11 - Behind the scenes logistics of integrating the program into retailer systems06:52 - Advice for retailers interested in adopting similar models09:00 - Evaluation results and program impact on Rhode Island households09:36 - Reaching vulnerable populations: children and the elderly11:43 - The potential for expanding incentives to other health behaviors and products12:19 - The concept of behavioral economics in promoting healthy choices13:21 - The possibility of broader incentive programs across health and activity sectors15:00 - Creative ideas for encouraging physical activity through retail and community efforts16:18 - The importance of partnership among government, private sector, and public health16:35 - The scalability of incentive programs and future opportunities17:21 - Final thoughts on collaborative efforts driving community health improvements18:07 - Closing remarksSupport the showFollow Bill on Instagram and YouTube

Hour 1 -- Copes and Ted Ramey give their thoughts on the Giants first half of the season. They also dive into Buster Posey's interview with the morning show and discuss Buster's thoughts heading into the trade deadline.See omnystudio.com/listener for privacy information.

Brooks sits down with Maren McCrary, a Talent ID Scout for US Soccer, to dig into what talent identification actually looks like at the highest level. Maren works on the girls' side at U.S. Soccer, but her path there ran through several college programs, where she coached and scouted before making the jump. They cover a lot of ground: the different roles Maren has held on her way to this position, why the best talent evaluators are upfront about what they're actually looking for instead of playing it close to the vest, and why there's no substitute for watching soccer — a lot of it, at every level. That last point matters more than people think: spotting a late bloomer who hasn't hit their growth spurt yet, or separating a kid who's just bigger and faster right now from one with real long-term potential, is one of the hardest parts of the job.If you loved this episode, drop us a review and rating — it genuinely helps us grow! ⚽

Sarah (Jessika Van) and Molly (Courtney Pouroso) receive some unfortunate marketing data in Grind (2026) Intensity:

Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826261424812

Resources for the Community:___________________________________________________________________Linktree Our Favorite ThingsNeed help appealing your GLP-1 dials? www.FindHonestCare.com/KimFind Your US Representatives https://www.usa.gov/elected-officials ______________________________________________________________________"Both Our Advice and our Guest Expert insights don't replace your own care team. Always talk to a doctor who can review your personal records and labs to make the safest choices for you."How GLP-1s Broke Diet CultureFor decades, we believed weight gain and weight loss were mostly about willpower, calories, and exercise. Today, we're learning there's much more happening beneath the surface. The biology that drives hunger, metabolism, weight gain, and long-term health is far more complex than we once understood.In this episode, Dr. Chiadi Ndumele, preventive cardiologist at Johns Hopkins Medicine and a leader with the American Heart Association, explains why GLP-1 medications work, how weight, metabolism, and chronic disease are connected, and why the first-ever Cardiovascular-Kidney-Metabolic (CKM) Clinical Practice Guideline represents a major shift in how we understand and treat weight-related disease. You'll also hear a powerful patient story that shows why this new understanding is giving hope to millions.In this episode:Why GLP-1 medications work when diets often don't.What really drives weight gain, weight loss, and long-term weight management.How metabolism, hormones, genetics, and overall health work together.Why understanding your body can help you advocate for the quality care you deserve.GuestDr. Chiadi NdumelePreventive Cardiologist, Johns Hopkins MedicineChair, 2026 American Heart Association/American College of Cardiology Cardiovascular-Kidney-Metabolic (CKM) Clinical Practice GuidelineResourcesAmerican Heart Association: New Cardiovascular-Kidney-Metabolic (CKM) Clinical Practice Guidelinehttps://www.heart.org/en/news/2026/06/09/new-ckm-guideline-urges-early-weight-talks-to-prevent-health-risksProfessional Heart Daily: 2026 Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndromehttps://professional.heart.org/en/science-news/2026-guideline-for-the-prevention-detection-evaluation-and-management-of-ckm-syndromeAmerican Heart Association News Release: First-Ever Clinical Practice Guideline for Cardiovascular-Kidney-Metabolic Syndromehttps://newsroom.heart.org/news/first-ever-guideline-on-cardiovascular-kidney-metabolic-syndrome-issued______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy #ObesityCare #PatientAdvocate #GLP1Community #RealGLP1StoriesSend us Fan Mail!Use Honest Care to Appeal GLP-1 Denials. Go to HonestCare.com/Kim  Honest Care can Appeal GLP-1 Denials. Go to FindHonestCare.com/Kim Support the showKim Carlos, Executive Producer TikTokInstagram Kat Carter,  Producer TikTokInstagram 

In this Episode of the Secure Your Retirement Podcast, Radon and Murs discuss what really happens during an evaluation appointment, the first Financial Advisor Meeting most people have when they start exploring what it actually takes to plan for retirement. They break down the five critical areas that determine Retirement Success, known as the ROUTE to Retirement: Retirement Risk Management, Retirement Income Planning, Medicare Planning and Long-Term Care Planning under one unified healthcare umbrella, Retirement Tax Planning, and Estate Planning. If you've ever wondered what separates a real Retirement Financial Plan from a portfolio review with a nice title, this episode lays out exactly where most plans quietly fall short.Listen in to learn about why a simple one-to-ten risk question reveals more about your Retirement Readiness than any account statement ever could, how a written Retirement Investment Strategy and a real Social Security Planning conversation change decision making for the better, and why Retirement Tax Strategies put in place before the calendar year ends can outweigh almost any other move you make on the road to retiring comfortably.In this episode, find out:Why the risk scale used in every evaluation appointment skips the number seven, and what your honest answer reveals about your true Retirement ReadinessHow a written retirement income plan and clear Social Security Planning turn a stressful guessing game into a Retirement Financial Plan with actual data behind itWhy Medicare Planning and Long-Term Care Planning are treated as one Unified Healthcare conversation, and what a dedicated Medicare specialist changes about that experienceWhy most people's Retirement Tax Planning happens too late to matter, and how proactive Retirement Tax Strategies executed before December 31st can beat any adjustment to an investment strategyWhat a five-year-old estate plan gets wrong, and the real story of a client who needed updated documents in a single week before leaving for a cruiseTweetable Quotes:"Retirement planning is a bunch of knobs, and if you turn one, you're turning all the others." - Murs Tariq"It's something people don't want to talk about, and it's easy to procrastinate on it because, hey, I'm good, I'm healthy." - Murs TariqWhether you're years from retiring or already retired, this episode doubles as a retirement checklist for anyone planning retirement who wants a second look at whether their plan for retirement actually holds up across all five areas. Retirement isn't one decision; it's five connected ones, and this episode walks through exactly how those five come together to help you secure your retirement with real confidence instead of a guess.Resources:If you are in or nearing retirement and you want to gain clarity on what questions you should be asking, learn what the biggest retirement myths are, and identify what you can do to achieve peace of mind for your retirement, get started today by requesting our complimentary video course, Four Steps to Secure Your Retirement!To access the course, simply visit POMWealth.net/podcast.

Show Notes: Shankar Ananth shares his background, mentioning his nine years of consulting experience, highlighting his experience at McKinsey and Bain, and his role  in building the new app, Micro-Casing.  Bridging the Gap in Case Interview Preparation Shankar explains the gap in case interview preparation methods, which led him to create Micro-Casing. He also mentions his eight years of experience as a case coach and the usefulness of the app for students. He discusses the target audience of the app, which includes consulting candidates and those looking to improve their consulting thinking. Micro-Casing - Your Case Partner Reimagined Shankar explains the homepage of the app, where users can log in through Google or Apple.  Quick start guide The app is designed as a decision-making tool with a multi-choice game-like interface to mimic case interviews.  Categories Users can choose from various categories like market entry, growth strategy, profitability, market size, or M&A.  Avoiding AI Hallucinations Shankar explains the gameplay, where users can pick a category, race the clock, and solve timed cases with two attempts. The app includes a feature where incorrect answers lead to rabbit holes, similar to real-life case interviews. The scoring system involves penalties for viewing hints and entering rabbit holes. Shankar highlights the app's manual case creation process to avoid AI hallucinations, ensuring the cases are accurate. Mock Case Interviews Demonstration The app's growth strategy category is described, showing the available cases and their status (completed or not started). Coaches Shankar explains the optional feature of selecting a sidekick or coach, which provides tips during the case.  Growth Dilemma They start a case called "ShopSphere's Growth Dilemma," where a case prompt is read and  the process of solving the problem begins.  Case Profitability The Summary Page Shankar explains the summary page, which shows the case details, difficulty, pass score, and performance metrics.  Case results and performance review The summary page includes a growth category readiness score and an overall readiness score, indicating progress and areas for improvement. He explores the view of all hints feature, which provides detailed feedback on each question. The Quality Control System Shankar discusses the process of creating and validating cases, involving AI-driven reviews and manual checks by experienced case coaches. The app currently has over 60 cases across various categories, ensuring rigorous quality control. Shankar mentions the potential for users to disagree with answers, which will be tracked for future improvements. The app aims to provide a comprehensive and accurate case preparation experience. The Leaderboard Feature Will and Shankar discuss the leaderboard feature, which allows users to compare their progress with others. The leaderboard is based on overall category readiness and overall readiness scores, calculated using various metrics. Shankar explains the option for colleges and consulting clubs to create their own leaderboards and case competitions within the app. The app supports private quizzing clubs, allowing organizations to upload and co-create cases for exclusive use. Shankar shares his experience as a case coach, starting from word-of-mouth referrals and eventually joining platforms to offer his services. Case Practice  for Consultants He highlights the importance of case practice for consulting candidates, noting that it can take months to prepare. Shankar offers listeners of the podcast two months of free access to the entire app, providing an opportunity to try it out. Timestamps: 03:07: Overview of Micro-Casing App 06:29: Gameplay and Scoring Mechanism  10:03: Detailed Walkthrough of the App 13:54: Evaluation and Feedback 16:59: Creation and Validation of Cases  20:14: Leaderboard and Customization Features Links: iOS: https://apps.apple.com/us/app/micro-casing/id6754453873 Android: https://play.google.com/store/apps/details?id=com.microcasing.dev&pcampaignid=web_share Special link / discount code for the general audience for a free 2 months:  iOS: https://apps.apple.com/redeem?ctx=offercodes&id=6754453873&code=2MOTS   Android:Use the code 'Umbrex' at checkout, not within the app  Special link / discount code for participants in the Umbrex Consulting Fellowship for a free 3 months:  iOS: https://apps.apple.com/redeem?ctx=offercodes&id=6754453873&code=UMB200  Android:Use the code 'UmbrexCore' at checkout, not within the app  This episode on Umbrex: https://umbrex.com/unleashed/episode-654-shankar-ananth-micro-casing-a-gamified-way-to-practice-case-interviews/ Unleashed is produced by Umbrex, which has a mission of connecting independent management consultants with one another, creating opportunities for members to meet, build relationships, and share lessons learned. Learn more at www.umbrex.com. *AI generated timestamps and show notes.  

MARVEL, a creative acronym meaning Microreactor Applications Research Validation and EvaLuation, is a trail blazing reactor development program designed to help the Idaho National Laboratory (INL) and the nuclear industry remember how to build and operate small nuclear reactors for testing and demonstration. The program was initiated in 2020 and has created many opportunities to learn and improve. The current MARVEL program lead, Dr. Abdalla Abou-Jaoude, joined me for Atomic Show #348 to talk about the program and its historic accomplishments. Even though the MARVEL reactor has not yet been completed, he and his team – both superiors and subordinates – consider the program to be a research and development success story. MARVEL is a micro reactor designed to produce 85 kilowatts of thermal energy. Using Stirling engines, it will be able to produce approximately 20 kilowatts of electricity. That’s about the same generating capacity as a whole house generator for a 4,000 square foot American suburban home. The reactor uses uranium-zirconium hydride (UZrH) fuel rods with uranium enriched to less than 20% U-235 (HALEU). They are similar to those used in Triga research reactors. The reactor coolant is NaK (sodium potassium eutectic) that is naturally circulated through the reactor core and the system heat exchangers. The early system design concept included directly-connected Stirling engines to convert reactor heat to electricity. That configuration was proven to be unworkable during a non nuclear thermal testing program called PCAT – Primary Coolant Apparatus Test. The Stirling engines vibrated enough to put the rest of the system at risk of rapid deterioration, so the design was changed to include a secondary, non radioactive NaK loop that then transferred its heat to a tertiary molten salt loop. This choice allows the Stirling engines and the heat conversion system to be placed outside of the building. That design change had the added benefit of making it easier to use the MARVEL reactor system to test various direct heat applications; with the directly mounted engines, it would have been difficult to extract any product other than electricity. A major benefit of a government funded research and development program like MARVEL is that it can provide widely accessible lessons learned. For a variety of commercial reasons, private sector programs are less likely to share what they have learned from their mistakes or dead end choices. Private sector participants can be hesitant to be the first to move, especially in a field where everyone knows that the existing government approval process is a major barrier that needs to be improved. A government funded program has the ability to approach and overcome the barriers without incurring the risk that they are simply making the path easier and smoother for their competitors. The cliche “don’t fight city hall” applies; it’s a somewhat easier battle when you are part of the city hall machinery. Abdalla explained how the MARVEL program leaders are happy to see how later projects are moving more quickly and even passing it to reach certain key development milestones. MARVEL leaders feel like they did their job by helping to exercise and improve the processes of review and approval. The program has also helped to give dozens of engineers more experience in the process of moving component and system designs off of computer screens and into real life fabrication. Numerous entities from universities, governments and the private sector are queuing up to use MARVEL to test various concepts for taking advantage of nuclear fission heat. Some of the potential uses include desalination (especially produced water from oil and gas wells), hydrogen production, micro grids, remote operations and training AI for reactor control. MARVEL is currently scheduled to achieve dry criticality in 2026. It should achieve full power operations in 2028. It is classified as a non capitalized asset, which limits its projected operating life to about 2 years. It has sufficient fuel to last longer if the decision is made to extend it past the two year point. Even if it operates a little longer, the plan is still to have it reach the decommissioning phase quickly enough to serve as a barrier breaker for that important life cycle phase. You are sure to enjoy the show and to learn something in the process.

Ant Cousins began his journey 25 years ago in technology roles for the British Ministry of Defence but quickly moved to Public Relations where he provided media advice to UK Forces in Iraq and Afghanistan countering Taliban propaganda. This experience led him to roles in Counter-Terrorism for the UK Home Office, where he focused on combatting Al-Qaeda's propaganda, and later to the Middle East during the Arab Spring or ‘Social Media Revolution'. In 2014 Ant started working exclusively in leadership roles in AI-focused startups, resulting most recently in him leading Factmata, an AI startup focused on detecting misinformation, through to an acquisition by the global Comms & PR tech provider, Cision. In May Ant joined Meltwater as VP of Product in charge of AI and Data.Ant is an accredited PR practitioner, member of the UK All Party Parliamentary group on AI, Chair of the Associated for the Measurement and Evaluation of Communications (AMEC) Tech-Hub and featured in PRWeek's 'Dashboard 25' in ‘23, ‘24 and ‘26. Quoted in The Times, Forbes, BBC, TechRound, PRWeek, PRMoment and others on the topic of AI, communications and misinformation.

Hour 4 - Another addition of Dear Derek, where listener from all over the world write into Dirty Work seeking advice from Derek Papa. Later the guys let you here their interview with Rich Aurilia where he give his thoughts on the Giants heading into the All-Star Break. See omnystudio.com/listener for privacy information.

Should your child get a neuropsychological evaluation? Neuropsychologist Dr. Joanna Jacobs explains what it reveals, who needs one, and why it's not scary. If you've ever been told your child might need a neuropsychological evaluation and felt your stomach drop, this episode is for you. Dr. Aliza Pressman sits down with neuropsychologist Dr. Joanna Jacobs to demystify what a neuro psych evaluation actually is, what it can tell you about your child's learning profile, and why so many parents leave the process feeling relieved rather than devastated. Whether your child is struggling with reading, attention, executive functioning, or social communication — or whether they seem fine on paper but something feels off at home — this conversation will help you understand what the evaluation process looks like, what questions to ask, and how to make sense of what you find out. What you'll learn: What a neuropsychological evaluation actually measures and who it's designed for  Why a diagnosis is a tool for accessing support, not a life sentence — and how to talk about it with your child at any age The critical difference between cognitive profile and disorder How neurodivergent brains, including those with dyslexia and ADHD, carry genuine strengths that language-based school systems frequently fail to identify or nurture This episode is brought to you by: OneSkin: Unlock your healthiest skin now and as you age. For a limited time, try OneSkin with 15% off using code RGH at oneskin.co/RGH Kodiak: Kodiak Bars help keep busy families fueled, satisfied, and ready for whatever the day brings. Find them at kodiakcakes.com or your local grocery store. Goodr: Ready to upgrade your eyewear to something functional, fashionable, fun, and affordable? Head to goodr.com/HUMANS to claim $10 off your first order. BetterHelp: You don't have to say yes to everything this summer. Find support in therapy. Sign up and get 10% off at BetterHelp.com/humans. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Access to care starts with knowing where care actually exists. New findings from the HHS Inspector General show that the provider information Medicaid patients and state officials rely on is often inaccurate or incomplete. Joining me now is Laura Kordish, Regional Inspector General for Evaluation and Inspections at Department of Health and Human Services Office of Inspector General.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Despite advances in open data, crucial questions remain about how data are being used and for what purposes. The Make Data Count initiative is driving progress on this front by building tools and community practices that help better measure, understand, and recognize the use and impact of data as an important research output.In this webinar, Make Data Count shared key updates from its ongoing projects, including insights from the Data Citation Corpus, a large, open collection of data citations, and the work with HELIOS Open to advance the implementation of data evaluation in institutional assessment processes. We also highlighted practical ways in which the community can get involved with data evaluation today.#openscience #data #citation #research #africa

Jane Dutton speaks to Minister in the Presidency responsible for Planning, Monitoring and Evaluation, Maropene Ramakgopa, about South African government collaborating with the UN to push towards Sustainable Development Goals for the next 5 years. The Midday Report with Mandy Wiener is 702 and CapeTalk’s flagship news show, your hour of essential news radio. The show is podcasted every weekday, allowing you to catch up with a 60-minute weekday wrap of the day's main news. It's packed with fast-paced interviews with the day’s newsmakers, as well as those who can make sense of the news and explain what's happening in your world. All the interviews are podcasted for you to catch up and listen to. Thank you for listening to this podcast of The Midday Report Listen live on weekdays between 12:00 and 13:00 (SA Time) to The Midday Report broadcast on 702 https://buff.ly/gk3y0Kj and on CapeTalk https://buff.ly/NnFM3Nk For more from The Midday Report go to https://buff.ly/BTGmL9H and find all the catch-up podcasts here https://buff.ly/LcbDdFI Subscribe to the 702 and CapeTalk daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Jane Dutton speaks to EWN Reporter, Nkosikhona Malingi-Mnisi about the court case involving Julius Mkhwanazi, and other senior Ekurhuleni officials. The Midday Report with Mandy Wiener is 702 and CapeTalk’s flagship news show, your hour of essential news radio. The show is podcasted every weekday, allowing you to catch up with a 60-minute weekday wrap of the day's main news. It's packed with fast-paced interviews with the day’s newsmakers, as well as those who can make sense of the news and explain what's happening in your world. All the interviews are podcasted for you to catch up and listen to. Thank you for listening to this podcast of The Midday Report Listen live on weekdays between 12:00 and 13:00 (SA Time) to The Midday Report broadcast on 702 https://buff.ly/gk3y0Kj and on CapeTalk https://buff.ly/NnFM3Nk For more from The Midday Report go to https://buff.ly/BTGmL9H and find all the catch-up podcasts here https://buff.ly/LcbDdFI Subscribe to the 702 and CapeTalk daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Jane Dutton speaks to DA's Tshwane Mayoral Candidate, Cilliers Brink, and National Chairperson of ActionSA, Michael Beaumont, to battle it out about Tshwane's Council suspending City Manager Johann Mettler and launching disciplinary action against CFO Gareth Mnisi. The Midday Report with Mandy Wiener is 702 and CapeTalk’s flagship news show, your hour of essential news radio. The show is podcasted every weekday, allowing you to catch up with a 60-minute weekday wrap of the day's main news. It's packed with fast-paced interviews with the day’s newsmakers, as well as those who can make sense of the news and explain what's happening in your world. All the interviews are podcasted for you to catch up and listen to. Thank you for listening to this podcast of The Midday Report Listen live on weekdays between 12:00 and 13:00 (SA Time) to The Midday Report broadcast on 702 https://buff.ly/gk3y0Kj and on CapeTalk https://buff.ly/NnFM3Nk For more from The Midday Report go to https://buff.ly/BTGmL9H and find all the catch-up podcasts here https://buff.ly/LcbDdFI Subscribe to the 702 and CapeTalk daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Jane Dutton speaks to EWN Reporter, Kgomotso Modise, to get the latest developments in the Madlanga Commission, including the launch of new IDAC Ombud to probe abuse of power complaints, maladministration. The Midday Report with Mandy Wiener is 702 and CapeTalk’s flagship news show, your hour of essential news radio. The show is podcasted every weekday, allowing you to catch up with a 60-minute weekday wrap of the day's main news. It's packed with fast-paced interviews with the day’s newsmakers, as well as those who can make sense of the news and explain what's happening in your world. All the interviews are podcasted for you to catch up and listen to. Thank you for listening to this podcast of The Midday Report Listen live on weekdays between 12:00 and 13:00 (SA Time) to The Midday Report broadcast on 702 https://buff.ly/gk3y0Kj and on CapeTalk https://buff.ly/NnFM3Nk For more from The Midday Report go to https://buff.ly/BTGmL9H and find all the catch-up podcasts here https://buff.ly/LcbDdFI Subscribe to the 702 and CapeTalk daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Catch Up on the latest leading news stories around the country with Mandy Wiener on Midday Report from 12:00 to 13:00. The Midday Report with Mandy Wiener is 702 and CapeTalk’s flagship news show, your hour of essential news radio. The show is podcasted every weekday, allowing you to catch up with a 60-minute weekday wrap of the day's main news. It's packed with fast-paced interviews with the day’s newsmakers, as well as those who can make sense of the news and explain what's happening in your world. All the interviews are podcasted for you to catch up and listen to. Thank you for listening to this podcast of The Midday Report Listen live on weekdays between 12:00 and 13:00 (SA Time) to The Midday Report broadcast on 702 https://buff.ly/gk3y0Kj and on CapeTalk https://buff.ly/NnFM3Nk For more from The Midday Report go to https://buff.ly/BTGmL9H and find all the catch-up podcasts here https://buff.ly/LcbDdFI Subscribe to the 702 and CapeTalk daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

For Good Things, Jane Dutton speaks to Brent Lindeque, about a student who asked for R60 for potatoes receiving overwhelming community support; SA Ballerina making history as first to graduate from a world-famous Academy; and three South African Hotels cracking ‘World’s Best’ Awards! The Midday Report with Mandy Wiener is 702 and CapeTalk’s flagship news show, your hour of essential news radio. The show is podcasted every weekday, allowing you to catch up with a 60-minute weekday wrap of the day's main news. It's packed with fast-paced interviews with the day’s newsmakers, as well as those who can make sense of the news and explain what's happening in your world. All the interviews are podcasted for you to catch up and listen to. Thank you for listening to this podcast of The Midday Report Listen live on weekdays between 12:00 and 13:00 (SA Time) to The Midday Report broadcast on 702 https://buff.ly/gk3y0Kj and on CapeTalk https://buff.ly/NnFM3Nk For more from The Midday Report go to https://buff.ly/BTGmL9H and find all the catch-up podcasts here https://buff.ly/LcbDdFI Subscribe to the 702 and CapeTalk daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Jane Dutton speaks to EWN Sports Reporter, Tholakele Mnganga, about Mbappé stunner ending Morocco resistance to send France into World Cup semi-finals. They also speak about what to expect at Wimbledon this weekend. The Midday Report with Mandy Wiener is 702 and CapeTalk’s flagship news show, your hour of essential news radio. The show is podcasted every weekday, allowing you to catch up with a 60-minute weekday wrap of the day's main news. It's packed with fast-paced interviews with the day’s newsmakers, as well as those who can make sense of the news and explain what's happening in your world. All the interviews are podcasted for you to catch up and listen to. Thank you for listening to this podcast of The Midday Report Listen live on weekdays between 12:00 and 13:00 (SA Time) to The Midday Report broadcast on 702 https://buff.ly/gk3y0Kj and on CapeTalk https://buff.ly/NnFM3Nk For more from The Midday Report go to https://buff.ly/BTGmL9H and find all the catch-up podcasts here https://buff.ly/LcbDdFI Subscribe to the 702 and CapeTalk daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Ellen and Christian return from their travels to review the good, the bad, and the ugly of the mongooses. We discuss the Shedd Aquarium and the Field Museum, historical plurals, neurotoxin Darth Vader, checking in with Pliny the Elder, the most "mean girls" scientific study ever, mysteriously weird pupils, the global issue of mongoose-induced ecological destruction, and so much more.  Works Cited: "Mongoose" - Etymonline “How the mongoose can fight the snake: The binding site of the mongoose acetylcholine receptor” - Dora Barchan et al., Proc. Natl. Acad. Sci. USA, August 1992 “Why the honey badger don't care: Convergent evolution of venom-targeted nicotinic acetylcholine receptors in mammals that survive venomous snake bites” - Danielle Drabeck et al., Toxicon, March 2015 Book 8, chapter 36 of Natural History - Pliny the Elder, 77 CE “Experimental evidence for delayed postconflict management behaviour in wild dwarf mongooses”  - Amy Morris-Drake et al, eLife, September 2021 Hawaii Invasive Species Council - Mongoose (Urva auropunctata) “Negative Impact of an Invasive Small Indian Mongoose Herpestes javanicus on Native Wildlife Species and Evaluation of a Control Project in Amami-Ohshima and Okinawa Islands, Japan” - Fumio Yamada & Ken Sugimura, Global Environmental Research, December 2004 Hazardous Substances and New Organisms Act 1996, Schedule 2 - New Zealand government Links: For more information about us & our podcast, head over to our website! Follow Just the Zoo of Us on BlueSky, Facebook, Instagram & Discord! Follow Ellen on Instagram or BlueSky! Help support this show and unlock bonus content! Become a member at https://maximumfun.org/joinjustthezoo

Ellen and Christian return from their travels to review the good, the bad, and the ugly of the mongooses. We discuss the Shedd Aquarium and the Field Museum, historical plurals, neurotoxin Darth Vader, checking in with Pliny the Elder, the most "mean girls" scientific study ever, mysteriously weird pupils, the global issue of mongoose-induced ecological destruction, and so much more.  Works Cited: "Mongoose" - Etymonline “How the mongoose can fight the snake: The binding site of the mongoose acetylcholine receptor” - Dora Barchan et al., Proc. Natl. Acad. Sci. USA, August 1992 “Why the honey badger don't care: Convergent evolution of venom-targeted nicotinic acetylcholine receptors in mammals that survive venomous snake bites” - Danielle Drabeck et al., Toxicon, March 2015 Book 8, chapter 36 of Natural History - Pliny the Elder, 77 CE “Experimental evidence for delayed postconflict management behaviour in wild dwarf mongooses”  - Amy Morris-Drake et al, eLife, September 2021 Hawaii Invasive Species Council - Mongoose (Urva auropunctata) “Negative Impact of an Invasive Small Indian Mongoose Herpestes javanicus on Native Wildlife Species and Evaluation of a Control Project in Amami-Ohshima and Okinawa Islands, Japan” - Fumio Yamada & Ken Sugimura, Global Environmental Research, December 2004 Hazardous Substances and New Organisms Act 1996, Schedule 2 - New Zealand government Links: For more information about us & our podcast, head over to our website! Follow Just the Zoo of Us on BlueSky, Facebook, Instagram & Discord! Follow Ellen on Instagram or BlueSky! Help support this show and unlock bonus content! Become a member at https://maximumfun.org/joinjustthezoo

Send us Fan Mail Function 1.2: Analysis and Evaluation of Data covers several essential topics that would make a great foundation for your podcast:Financial Analysis & Modeling: Analyzing individual companies, comparable companies, and specific industry sectors, as well as building spreadsheets and financial models using basic accounting and statistical concepts.The Balance Sheet: Breaking down assets (such as cash, marketable securities, inventory, PP&E, and goodwill), liabilities (like short-term debt, accounts payable, and long-term debt), and stockholders' equity/net worth (including preferred/common stock and retained earnings).The Income Statement: Understanding the flow from revenue/sales down to net income, including COGS (fixed and variable costs), SG&A expenses, depreciation/amortization, operating income, and taxes.The Cash Flow Statement: Exploring the three main pillars: operating cash flow, investing cash flow, and financing cash flow.Support the show

The fastest way to kill a good learning goal is to blame the format instead of fixing the design. We're kicking off a new series on myths in instructional design and education by taking on one of the biggest, most stubborn claims out there: online learning is less effective than in-person learning.We get why this belief sticks. A lot of digital learning has felt disconnected, confusing, passive, or overwhelming, especially when people experienced emergency remote teaching that was rushed and under-supported. But a bad online course doesn't prove online education fails. It proves the learning experience wasn't designed for that environment. When we stop diagnosing the medium and start diagnosing the learning, we see the real levers that drive outcomes.We also ground the conversation in evidence-based practice, including insights from the U.S. Department of Education's “Evaluation of Evidence-Based Practices in Online Learning.” The takeaway isn't “online is better” or “in-person is better.” The takeaway is that performance depends on factors like time on task, instructional elements, collaboration, and the overall quality of the instructional strategy.Then we get practical. We walk through what strong e-learning and digital learning design actually require: clear navigation, meaningful activities, interaction with purpose, timely feedback, and accessibility and learner support. You'll leave with a simple “myth reset” challenge and a set of questions you can use to audit one lesson, module, or training and make one small improvement right away.Subscribe, share this with a fellow educator or instructional designer, and leave a review if it helped. What's one online course you've seen that could have been great with better design?

Viele Menschen schreiben ihre Erfolge dem Zufall zu und haben Angst, irgendwann als „Hochstapler“ entlarvt zu werden. Woher diese Selbstzweifel kommen, wen sie besonders betreffen und welche Strategien helfen können, erklärt Sonja Rohrmann, Professorin für differentielle Psychologie & Psychologische Diagnostik, Dekanin des Fachbereichs für Psychologie und Sportwissenschaften und Leiterin der Arbeitsstelle für Diagnostik & Evaluation an der Goethe-Universität Frankfurt. Außerdem schauen wir uns einen ganz wichtigen Sinn an, ohne den unser Leben ganz schön langweilig wäre: unseren Geschmacksinn. Hier findet Ihr eine Studie zum Impostor-Phänomen: https://so06.tci-thaijo.org/index.php/IJBS/article/view/521/pdf Produktion: Lilian Hoenen Redaktion: Antonia Beckermann Noch mehr "Aha!"- Folgen gibt es bei WELTplus und Apple Podcasts. Alle zwei Wochen am Montag eine neue Folge. Hier bei WELT hören: https://www.welt.de/podcasts/aha-zehn-minuten-alltags-wissen/plus246844328/Noch-mehr-Alltagswissen-Aha-Bonus-Folgen-fuer-Abonnenten-Podcast.html. "Aha! Zehn Minuten Alltags-Wissen" ist der Wissenschafts-Podcast von WELT. Wir freuen uns über Feedback an wissen@welt.de. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Dila Odluyurt, senior reporter, covering the Turkish PE, PP and PVC markets speaks about:Listen to our Global PE, PP and PVC markets evaluation, with focus on Turkish market How is the Turkish market doing our last update in March How the lowering prices affected the market dynamics How demand has been for the past 3 months What is the current situation in the market

In this must-listen episode, Dr. Ryan Moenster is joined by Dr. Monica Mahoney and Dr. Mark Gilchrist to dive deep into the evolving landscape of outpatient parenteral antimicrobial therapy (OPAT) and complex outpatient antimicrobial therapy (CoPAT), highlighting real-world challenges, patient selection, and emerging treatment strategies. Navigating outpatient antimicrobial management can be complex, but this episode breaks down key insights and practical applications to help clinicians optimize care beyond the hospital. References: 1.       Noble AL, Patel S, Birnie E, et al. 2026 updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK. JAC Antimicrob Resist. 2026;8(2). 2.       British Society for Antimicrobial Chemotherapy (BSAC). OPAT Global Summit 2027. 3.       Naicker S, Roberts JA, Cheng V, et al. A review of antimicrobial stability testing guidance for outpatient parenteral antimicrobial therapy programmes: Is it time for global harmonization of testing frameworks? JAC Antimicrob Resist. 2024;6(6). 4.       Gilchrist M, Jamieson C, Drummond F, et al. Assessment of ceftolozane/tazobactam degradation profile and toxicity data in elastomeric devices for continuous infusion via outpatient parenteral antimicrobial therapy (OPAT). JAC Antimicrob Resist. 2023;5(2). 5.       Naicker S, Roberts JA, Won H, et al. Evaluation of the stability of ceftazidime/avibactam in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy utilizing a national stability protocol framework. JAC Antimicrob Resist. 2024;6(2). 6.       Wolie ZT, Unwin S, Burke A, et al. Evaluation of the stability of tigecycline in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy. JAC Antimicrob Resist. 2025;7(3). 7.       Solomon DA, Beieler AM, Levy S, et al. Perspectives on the use of outpatient parenteral antibiotic therapy for people who inject drugs: Results from an online survey of infectious diseases clinicians. Open Forum Infect Dis. 2023;10(7):ofad372. doi:10.1093/ofid/ofad372. 8.       Yagnik KJ, Brown LS, Saad HA, et al. Implementation of IV push antibiotics for outpatients during a national fluid shortage following Hurricane Maria. Open Forum Infect Dis. 2022;9(5):ofac117. doi:10.1093/ofid/ofac117. 9.       Boettcher SR, Kenney RM, Everson NA, et al. Discharge delays and costs associated with outpatient parenteral antimicrobial therapy for multidrug-resistant organisms: A retrospective cohort study. Open Forum Infect Dis. 2025;13(1):ofaf770. 10.   Rivera CG, Mara KC, Mahoney MV, Ryan KL. Survey of pharmacists on their roles and perceptions of outpatient parenteral antimicrobial therapy in the United States. Antimicrob Steward Healthc Epidemiol. 2022;2(1):e69. 11.   Rapoport AB, Fischer LS, Santibanez S, et al. Infectious diseases physicians' perspectives regarding injection drug use and related infections—United States, 2017. Open Forum Infect Dis. 2018;5(7):ofy132. doi:10.1093/ofid/ofy132. 12.   Turner NA, Hamasaki T, Doernberg SB, et al.; Antibacterial Resistance Leadership Group. Dalbavancin for treatment of Staphylococcus aureus bacteremia: The DOTS randomized clinical trial. JAMA. 2025;334(10):866–877. doi:10.1001/jama.2025.12543. 13.   Volk CF, Hutson PR, Rose WE. Simulated target attainment of multidose regimens of dalbavancin for prolonged durations of therapy. Open Forum Infect Dis. 2024;11(6):ofae315. doi:10.1093/ofid/ofae315. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Instagram: @SIDPharm ( https://www.instagram.com/sidpharm/) or @breakpointspodcast_sidp (https://www.instagram.com/breakpointspodcast_sidp/) https://www.instagram.com/breakpointspodcast_sidp/?hl=en Facebook: https://www.facebook.com/sidprx LinkedIn:  https://www.linkedin.com/company/sidp/ SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

How is portal vein embolization (PVE) pushing the boundaries of liver tumor resectability, and what does it take to induce hypertrophy without compromising the remnant liver? In this episode of the BackTable Podcast, interventional radiologist Dr. David Madoff of Yale University joins Dr. Michael Barraza to discuss the pathophysiological rationale, technical considerations, and emerging clinical paradigms of performing PVE to augment the future liver remnant (FLR) prior to resection and reduce the risk of postoperative liver failure. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by RADPAD® Radiation Protectionhttps://www.radpad.com/ --- Timestamps 00:00 - Introduction02:14 - IO Practice and Research07:25 - PVE Indications and Adequate FLR12:55 - Referrals and Patient Selection17:27 - PVE vs. Y90 Radiation Lobectomy22:12 - Liver Venous Deprivation25:31 - Measuring FLR Function30:11 - Procedural Planning and Technique36:36 - Preferred Embolic Agents and Challenges46:58 - Ipsilateral vs. Contralateral Access50:52 - Complications, Medications, and Follow-Up55:45 - Final Thoughts and Closing Remarks --- More about this episode The physicians dissect the anatomic and oncologic benchmarks used to select PVE candidates, including FLR volumetric thresholds for normal, steatotic, and cirrhotic livers. Dr. Madoff walks through his procedural technique, detailing catheter maneuvers and embolic administration, emphasizing the importance of evaluating for anatomic variants, and explaining the benefits of using an ipsilateral approach to protect the FLR. The doctors critique ongoing debates in hepatic augmentation, assess the complementary relationship between PVE and Y90 radioembolization, and discuss the outcomes and risks associated with different embolic agents. They stress the importance of patient selection and assessment protocols that go beyond static volumetric measurements to incorporate functional parameters for better prediction of regenerative kinetics and clinical outcomes. The episode concludes with a review of postprocedural follow-up and potential complications, highlighting the importance of considering pathophysiologic dynamics of both the tumor and the anticipated liver remnant to ensure successful treatment. --- Resources DRAGON Trialhttps://www.dragontrial.com/ Three hundred and one consecutive extended right hepatectomies: Evaluation of outcome based on systematic liver volumetryhttps://doi.org/10.1097/SLA.0b013e3181b674df Portal vein embolization with N-butyl-cyanoacrylate improves liver hypertrophy compared to microparticles – A Swedish multicenter cohort studyhttps://doi.org/10.1016/j.heliyon.2023.e21210 --- BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

We totally forgot yesterday was the anniversary of Nebraska joining the Big Ten, Creighton joining the Big East, and Omaha joining the Summit League. We make that up by evaluating the past decade of local athletics in their current conferences.

Join Bill and Chris as they review and discuss two obscure sci-fi and action films, 'Brain Twisters' and 'The Evil That Men Do,' exploring their plot, production, and entertainment value. Analysis of 'Brain Twisters' plot and production Discussion of 'The Evil That Men Do' and Charles Bronson's performance Comparison of film styles and pacing Insights into 1980s and 1990s genre filmmaking Evaluation of film quality and entertainment value

Jonathan and Daryl highlight the Guardians' recent win and Austin Hedges' offensive contributions before debating the Cleveland Browns' handling of Shedeur Sanders. They also explore LeBron James' growing obsession with golf and how Northeast Ohio's weather could impact his future. 01:00 - Austin Hedges' Performance 02:17 - Sanders Evaluation 08:30 - LeBron's Golf Obsession

The FiltrateJoel Topf kidneyboy.bsky.socialSwapnil Hiremath @hswapnil.medsky.social Pedro Teixeira @nephcrit.bsky.socialSpecial GuestsEwout J. Hoorn, Professor of Medicine Erasmus MC, Netherlands. One of the primary authors.Harish Seethapathy, Assistant physician at Massachusetts General HospitalEditingVipin VergheseThe Kidney Connection written and performed by Timothy YauShow Notes A Randomized Trial of Targeted Hyponatremia Correction in Hospitalized Patients in NEJM Evidence, in PubMed, in NephJCSeethapathy: Severe Hyponatremia Correction, Mortality, and Central Pontine Myelinolysis in NEJM EvidenceMacMillan: Osmotic Demyelination Syndrome in Patients Hospitalized with Hyponatremia in NEJM EvidenceSALSA: Risk of Overcorrection in Rapid Intermittent Bolus vs Slow Continuous Infusion Therapies of Hypertonic Saline for Patients With Symptomatic Hyponatremia: The SALSA Randomized Clinical Trial in JAMA Internal MedicineSALT 1 and 2: Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia in NEJM Hyponatremia registry: Current treatment practice and outcomes. Report of the hyponatremia registry in Kidney InternationalThe Richard Sterns' article on the lower mortality with more severe hyponatremia: Mortality and Serum Sodium: Do Patients Die from or with Hyponatremia? in CJASNThe European Hyponatremia Guidelines: Clinical practice guideline on diagnosis and treatment of hyponatraemia in The European Journal of EndocrinologyThe American Hyponatremia Guidelines: Diagnosis, Evaluation, and Treatment of Hyponatremia: Expert Panel Recommendations in American Journal of MedicineTreating hyponatremia: damned if we do and damned if we don't by Tom Berl in Kidney InternationalProspective (clamp) versus reactive (rescue) DDAVP in hyponatremia: Safety and efficacy of proactive versus reactive administration of desmopressin in severe symptomatic hyponatremia: a randomized controlled trial in Nature Scientific Reports and as covered in PBFluidsHelbert Rondon's RCT of urea Urea for Chronic Hyponatremia on ClinicalTrials.govTubular SecretionsSwapnil: Catfishing on CatNet: A Novel by Naomi Kritzer (Amazon)Harish: Disney CruiseEdward: Flesh: A Novel (Booker Prize Winner) by David Szalay (Amazon)Pedro: Scrubs reboot (IMDB)Joel: KIDNEYcon

It's In the News - a look at the top diabetes headlines and stories happening now. Our top stories: More information about type 1 and COVID, including the vaccine, why is the latest GLP-1 medication, not yet FDA approved, showing up all over the place, what table sugar and vinegar could mean for drug costs, a new inhaled insulin study and much more  I'll see you at Friends for Life next week. Come find me at Table T18 Learn more about our in-person events here: https://diabetes-connections.com/events/ Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Transcript & links:    Okay.. our top story this week: XX A large Swedish study found that the increased risk of being diagnosed with type 1 diabetes after COVID-19 infection is mostly limited to the first 30 days after infection and does not continue long term. Researchers followed nearly the entire Swedish population under age 80 from 2020 through 2023 and found that while SARS-CoV-2 infection was linked to a temporary rise in new type 1 diabetes diagnoses, the risk declined over time. The study also found no evidence that COVID-19 vaccination increases the long-term risk of developing type 1 diabetes. Vaccination did not significantly change the relationship between COVID-19 infection and diabetes risk, and any small increase in diagnoses seen among adults shortly after a first vaccine dose was not seen after later doses or during longer follow-up. The researchers concluded that their findings do not support changing current COVID-19 vaccination recommendations because of concerns about type 1 diabetes risk. https://www.infectiousdiseaseadvisor.com/news/covid19-infection-may-increase-short-term-type-1-diabetes-risk/ XX Two new studies are challenging the traditional view that type 1 diabetes develops solely because the immune system attacks insulin-producing beta cells. Researchers from Indiana University found evidence that beta cells themselves may play an active role in determining whether they survive or succumb to the stresses that lead to type 1 diabetes. In the first study, scientists discovered that some healthy human beta cells can quickly activate an antiviral defense system when exposed to interferon-alpha, an immune signal often produced during viral infections. This response relies on molecules called reactive oxygen species (ROS), which are usually associated with cell damage but, in this case, appeared to help switch on protective antiviral genes. Researchers found this defense program in healthy cells and in people at risk for type 1 diabetes, but not in beta cells from people who already had the disease. The findings suggest that losing this built-in defense mechanism may make beta cells more vulnerable during the development of type 1 diabetes. The second study focused on autophagy, the process cells use to recycle damaged or worn-out components. Using a new imaging technique, researchers observed that beta cells in a mouse model of type 1 diabetes showed defects in autophagy before blood sugar levels began to rise and even before a full immune attack was underway. This suggests that problems inside the beta cells may occur early in the disease process rather than being caused entirely by the immune system. Together, the studies point to a more complex picture of type 1 diabetes. While they do not show that beta-cell defects cause the disease, they suggest that differences in how beta cells respond to stress, viral signals, and cellular damage may influence who develops type 1 diabetes and how the disease progresses. https://medicalxpress.com/news/2026-06-beta-cells-players-diabetes.html XX Researchers have created the most detailed map yet of how the human pancreas develops during childhood, offering new clues about why children are especially vulnerable to developing diabetes. The study, published in Nature Communications, examined pancreatic tissue from 123 children without diabetes, ranging from newborns through age 10. Using advanced imaging techniques, scientists tracked how insulin-producing islet cells grow and mature during the first decade of life. The researchers found that pancreas size varies dramatically at birth, with some infants having pancreases nearly four times larger than others. They also discovered that insulin-producing beta cells grow more slowly after birth than previously thought, suggesting that much of a person's lifelong beta cell capacity may be established before birth and during early childhood. Other findings showed that insulin-producing cells mature earlier than glucagon-producing cells and that new hormone-producing cells may continue to form after birth. The researchers hope this new understanding of pancreas development will help scientists identify diabetes risk earlier and develop better strategies for prevention and treatment in children. https://news.vumc.org/2026/06/29/unlocking-diabetes-secrets-pediatric-organ-donors-help-map-a-path-to-a-cure-and-prevention/   XX At the American Diabetes Association annual meeting, 2-year results from the SUPPRESS-EARLY trial showed that initiating tirzepatide (Mounjaro, Zepbound) early in the course of type 2 diabetes led to substantially higher rates of near-normal glycemic control and also led to broader metabolic improvements compared with intensive conventional therapy.   In this MedPage Today video, investigator Stefano Del Prato, MD, of the University of Pisa in Italy, discusses the findings.     Following is a transcript of his remarks:   What happened is that in the tirzepatide-treated arm, 85% of the population at the end of the second year was on the maximum dose of tirzepatide 15 mg. And then the remaining 15 with the different doses.   Interestingly, in the population that had been treated with the intensive conventional approach, 85% of them ended up to have, on top of metformin, a GLP-1 receptor agonist, mainly represented by subcutaneous semaglutide [Ozempic, Wegovy], 60+%, another 15% on oral semaglutide [Rybelsus], and the remaining on dulaglutide [Trulicity].   And I have to say that maybe the recommendation to really push along the line to try to achieve and to strive to achieve [glycemic] control was successful in these individuals. Because the population that had been recruited in the study started off with a baseline A1C of 7.8% and it went down to 6.3% in the conventionally intensive treatment, which is not bad at all, on average is below the target of 6.5%.     However, when we look at the effect of tirzepatide, the final level of A1C at the end of the second year was 5.6%, which is on average below the upper limit of the normal range for A1C, 5.7%. This also translates into more people not only achieving normal glycemia, if we can define normal glycemia as A1C below 5.7%, greater than what we observed in conventionally treated individuals. So it was around three times more people achieving an A1C of 5.7%, in the range of around 65%, as compared to 28% with people on a conventional optimized treatment.   Now, this is not surprising knowing the potency of tirzepatide. But again, going back to the rationale of the design, can we change what is the natural history of the disease? This seems to be at least of interest and it's possibly changing the trajectory of the disease for glycemic control, as I mentioned, but also in terms of the body weight and waist circumference because both body weight and waist circumference went much lower with tirzepatide compared to the conventional treatment.   Tirzepatide also was associated with an improvement in the lipid profile, in particular with the LDL, triglycerides, and the triglyceride concentration and non-HDL cholesterol, and also with a statistically significantly lower systolic blood pressure with a numerical reduction in the diastolic blood pressure.   And also the other thing that probably will ... become more apparent with the study continuing is that the investigators were allowed to add on any other treatment ... needed to achieve their target. So tirzepatide was just metformin and tirzepatide. In the control group, there was already 10% of people who were receiving two drugs on top of the metformin.   So another potential result of the trial is that it's possible to achieve and maintain better glycemic or better metabolic control over the time without really needing to increase the number of medications in order to achieve that goal. And we know that type 2 diabetes is a progressive condition often requiring intensification of the treatment.   So these initial results really stand for a great opportunity with tirzepatide. Of course, we need to wait for the 4 years just to confirm that this is indeed the case, but the initial result seems to point along that line. https://www.medpagetoday.com/meetingcoverage/adavideopearls/121967 XX A study from the University of Virginia found that high blood pressure is extremely common among people with diabetes, even among those who believe their blood pressure is under control. Researchers measured blood pressure in 172 adults with type 1 or type 2 diabetes during routine eye clinic visits and found that only 8% had normal readings. About half had stage 2 hypertension, and more than 10% had blood pressure levels high enough to be considered a medical emergency. The study also revealed that many patients were unaware of how serious their blood pressure problems were. Among those who thought their hypertension was well controlled, more than half still had stage 2 hypertension. Nearly 60% of participants were advised to contact their primary care provider, and one patient required an emergency department referral. Most patients supported blood pressure screening during eye exams, leading researchers to suggest that routine blood pressure checks in ophthalmology clinics could help identify undiagnosed or poorly controlled hypertension before it leads to serious complications such as heart attack, stroke, or worsening diabetic eye disease. https://medicalxpress.com/news/2026-06-routine-eye-exams-reveal-stage.html XX What is going on with retatrutide? This is the next generation GLP-1 but it's not authorized outside of clinical trials. Big investigation by CBS shows retatrutide is for sale all over the internet, a phenomenon they say has no modern precedent. CBS News identified more than 120 websites selling or promoting retatrutide, including more than 50 clinics staffed by licensed medical professionals. After being contacted by CBS News, at least 21 clinics abruptly removed retatrutide from their websites or changed the language to state they don't offer it. Others defended prescribing it, saying they're confident enough in results from clinical trials sponsored by drugmaker Eli Lilly that they didn't need to wait for the FDA's independent, rigorous review. An FDA spokesperson said retatrutide "has not been found safe or effective for any condition," adding that it "cannot be manufactured or distributed except for investigational use." The Justice Department is prosecuting two cases – in Utah and Florida – involving the sale and prescription of retatrutide. But the first line of enforcement is often at the state level. Ohio's Board of Pharmacy has taken action against several pharmacies and clinics providing retatrutide, and just last month, Alabama's Medical Board warned physicians against prescribing research-grade medications. The FDA has sent 14 warning letters to companies that have advertised retatrutide since 2024. Of these, at least six have continued to offer it online, including a business called Pink Pony Peptides. A TikTok account associated with the firm responded to the warning in April by taunting the FDA, boasting that the business "just had the best 24 hours ever." In May, Eli Lilly announced that participants in a large clinical trial taking the highest dose of retatrutide lost an average of 28% of their body weight over 80 weeks. Side effects – including nausea, diarrhea, constipation and vomiting – were comparable to similar therapies, the company said. "Anyone purporting to sell retatrutide to consumers is breaking the law," an Eli Lilly spokesperson said https://www.cbsnews.com/projects/2026/experimental-weight-loss-drug/ XX Pioneering research has developed a new way of creating carbohydrate-based medicines, which could ultimately replace costly drugs for common health conditions, using two cheap basic ingredients – table sugar and vinegar. These medications include SGLT2 inhibitors, widely prescribed drugs used to treat type 2 diabetes, heart failure and chronic kidney disease. Co-lead author Professor Phil Baran, Dr. Richard A. Lerner Endowed Chair at Scripps Research, in San Diego, California, said: "The point of this is to show that anyone in a garage can make an SGLT2 inhibitor with reagents that are widely available. We have not patented this method, so we welcome any generic drug company – or anyone else – who wants to use it to help bring costs down for patients." https://www.newswise.com/articles/new-study-shows-table-sugar-could-hold-a-cheaper-quicker-key-to-making-vital-drugs-for-diabetes-heart-failure-and-chronic-kidney-disease XX England and Wales approve teplizumab to slow progression of T1D. At the moment, the Scottish Medicines Consortium does not have an appraisal of Tzield on the go, so, there is likely to be a disparity in access within the UK for the time being. In Northern Ireland, access will depend on a review and adoption of NICE guidance.  Sanofi is expecting to see an uptick in momentum thanks to two subsequent FDA approvals, one in children as young as one with stage 2 T1D, and a second to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 T1D. btw you might here more people referring to stage 4 diabetes. They've added that to include people diagnosed with type 1 who've been on insulin for a longer period of time – basically long enough to not be eligible for the current guidelines for Tzield. https://www.bbc.com/news/articles/ce8mzd94r76oXX XX Obesity Association, a division of the American Diabetes Association® (the association), announced the next section in the Standards of Care in Overweight and Obesity, "Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults," published in Diabetes, Obesity, and CardioMetabolic CARE® and BMJ Open Diabetes Research & Care.  Key highlights of the guidance: Early screening: Annual BMI screening with emphasis on tracking weight trends to identify risk earlier, including a longitudinal life-event weight graph tool for standardized assessment. Enhanced diagnosis: Combines BMI with waist measurements and population-specific thresholds to improve accuracy. Notably, the guidelines recommend that BMI in the overweight range together with central adiposity measurements warrant a formal obesity diagnosis. Comprehensive evaluation: Holistic assessment including medical, behavioral, and social factors. Offers a fully integrated obesity diagnostic algorithm. Risk stratification: Use of tools like the Edmonton Obesity Staging System to guide care. Chronic care approach: Ongoing monitoring and follow-up to support long-term management. Reducing bias: Promotes person-centered, non-stigmatizing care and system-level improvements at the clinical workflow level and encourages screening for prior weight bias/stigma experiences. https://www.prnewswire.com/news-releases/new-standards-of-care-in-overweight-and-obesity-section-screening-diagnosis-evaluation-and-staging-of-obesity-in-adults-302809670.html XX Dexcom (Nadsaq:DXCM) today announced the launch of its fully reimagined Stelo over-the-counter (OTC) sensor app experience. San Diego-based Dexcom plans to formally begin the new app rollout in July for Apple iPhone and Android users in the U.S. Dexcom said its reimagined app aims to make glucose insights easier to understand and act on. It hopes to help build awareness of how food, activity, sleep and stress influence overall wellbeing.   The company also reiterated plans to launch Stelo internationally. It expects to bring the sensor to the UK, Australia, New Zealand and South Korea later this year, continuing into 2027. https://www.drugdeliverybusiness.com/dexcom-launches-enhanced-stelo-app/ XX MannKind Corporation recently announced it received a grant from Breakthrough T1D to support the INHALE-1 clinical study of Afrezza, its ultra rapid-acting inhaled insulin, in newly diagnosed pediatric type 1 diabetes patients aged 10 to under 18 years. This external funding for a trial focused on early use of Afrezza in children highlights growing third-party support for inhaled insulin in pediatric diabetes care. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/afrezza-pediatric-trial-grant-might-change-the-case-for-inve XX Alexander Zverev heads into Wimbledon with plenty of momentum. The French Open champion returns to the All England Club looking to build on his first Grand Slam title and gain ground on Carlos Alcaraz in the race for the No. 2 spot in the ATP rankings. Zverev has an opportunity to make up points quickly after a first-round exit at Wimbledon last year. But his final tune-up before Wimbledon came with an unexpected challenge. During his semifinal loss to Taylor Fritz at the Halle Open, Zverev said a malfunctioning glucose sensor led to serious diabetes management issues on court. The sensor incorrectly showed his blood sugar was high when it was actually low, causing him to take more insulin than needed. "I had huge problems with the sugar because the sensor I use gave me a completely incorrect reading," Zverev said after the match. "During the match, or rather during the first 45 minutes, I had to consume about 350 grams of sugar. I felt absolutely terrible." Despite feeling unwell, Zverev pushed the match to three sets before falling 6-7(4), 6-4, 7-5 to Fritz. He credited his opponent with playing the better match and said the diabetes-related issue was not an excuse for the result. Zverev, who was diagnosed with type 1 diabetes at age 4, uses Medtronic diabetes technology to help manage his glucose levels while competing on the ATP Tour. He said the sensor error was the first major problem he has experienced after nearly a decade of using the technology. The German said the incident should not affect his Wimbledon preparations. With the sensor issue behind him, Zverev will begin his Wimbledon campaign focused on adding another strong result to what has already been a breakthrough season.   https://www.reuters.com/sports/tennis/zverev-says-glucose-sensor-malfunction-affected-halle-semi-final-loss-fritz-2026-06-21/

Learn more about Level 1 Functional Pelvic Health Practitioner programGet certified in pelvic health from the OT lens hereGrab your free AOTA approved Pelvic Health CEU course here.____________________________________________________________________________________________Pelvic OTPs United - Lindsey's off-line interactive community for $39 a month! Inside Pelvic OTPs United you'll find:​Weekly group mentoring calls with Lindsey. She's doing this exclusively inside this community. These aren't your boring old Zoom calls where she is a talking head. We interact, we coach, we learn from each other.​Highly curated forums. The worst is when you post a question on FB just to have it drowned out with 10 other questions that follow it. So, she's got dedicated forums on different populations, different diagnosis, different topics (including business). Hop it, post your specific question, and get the expert advice you need.More info here. Lindsey would love support you in this quiet corner off social media! 

As the NFL Top-100 list starts to get released, Brock and Salk discuss who from the Seahawks they thing will be on the list. They recap the Mariners win over the Pirates, talk about possible NBA expansion to Seattle, and more in Need to Know. Aaron Goldsmith joins the show to talk about the return to form of both Cal Raleigh and Andres Munoz, the recent up-tick in velocity from some of the Mariners pitchers, his impression of Cole Young, and they revisit one of Goldy's most infamous calls.